Centrus Energy Corp vs Tempus AI — how do they compare? Centrus Energy Corp trades at $142.44 (market cap $2.91B), while Tempus AI trades at $70.93 (market cap $12.58B). The key difference: Tempus AI is far larger — about 4.3× Centrus Energy Corp's market cap, and Tempus AI is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 29 Days and Tempus AI for 23 Days on average.
| LEU | TEM | |
|---|---|---|
Market Cap | $2.91B | $12.58B |
Volume | 903,777 | 7,444,569 |
Sector | Energy | Broad Market / Factor |
52-Week High | $436.00 | $96.39 |
52-Week Low | $138.18 | $41.55 |
Typical Hold Time | 29 Days | 23 Days |
Enterprise Value | $2.22B | $13.21B |
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $142.09, down 3.43% on the day, with technical indicators showing a bearish trend. The company reported mixed quarterly results, missing Q4 2025 EPS estimates but beating in Q1 and Q2 2026. Recent news highlights Centrus as a key player in the nuclear fuel supply chain, securing multiple HALEU contracts amid growing nuclear energy demand. Valuation metrics appear elevated with a P/E of 75.18 and P/S of 6.68, while profitability metrics show a net income margin of 10.23% and ROE of 8.05%.
The outlook for LEU is cautiously optimistic, supported by strategic positioning in the nuclear fuel market and recent contract wins. However, high valuation multiples and recent earnings volatility present risks. Analyst consensus is mixed with 46% buy ratings and a $218.10 price target, suggesting potential upside if execution improves. Key risks include execution challenges, competitive pressures, and dependence on nuclear energy policy support.
Tempus AI (TEM) trades at $69.28, down 1.44% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth (2026: $1.4B) but remains unprofitable with negative margins. Recent FDA clearance for ECG-MR AI product and ESMO Congress presentations highlight innovation momentum. Analyst consensus is strongly bullish with 64% buy ratings and $72.60 price target.
TEM offers growth potential in AI-driven healthcare diagnostics but carries significant execution risk due to persistent losses. The stock's high P/S ratio (8.61) reflects growth expectations, yet negative ROE (-67.44%) and insider selling warrant caution. Upside depends on profitability improvements and commercial adoption of new AI products.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →